# The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence

> **NCT06166615** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 148 (estimated)

## Conditions studied

- Fecal Incontinence

## Interventions

- **DRUG:** Ramosetron
- **DRUG:** Psyllium

## Key facts

- **NCT ID:** NCT06166615
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-15
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-11-01
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06166615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06166615, "The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06166615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*